SCHEMBL6605794

SCHEMBL6605794

NCCCNc1nc(N)c(C(=O)c2cccc(OCc3ccccc3)c2)s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK5 Q00535 6/20 0.58
GSK3A P49840 2/20 0.58
GSK3B P49841 2/20 0.58
CLK2 P49760 1/20 0.58
CDK9 P50750 1/20 0.58
LIMK1 P53667 1/20 0.58
DYRK1A Q13627 1/20 0.58
CLK4 Q9HAZ1 1/20 0.58
DYRK1B Q9Y463 1/20 0.58
CCNA2 P20248 9/20 0.56
CDK2 P24941 9/20 0.56
CDK5R1 Q15078 5/20 0.53
KDM4E B2RXH2 1/20 0.52
TP53 P04637 1/20 0.52
HTT P42858 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
HIF1A Q16665 1/20 0.52
ZAP70 P43403 1/20 0.52
CCNE1 P24864 1/20 0.48
MAPT P10636 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6605716 0.85 CDK5 (0.52) CDK5GSK3AGSK3BCLK2CDK9
SCHEMBL6616475 0.85 CDK5 (0.52) CDK5GSK3AGSK3BCLK2CDK9
SCHEMBL7758141 0.84 CCNA2 (0.76) CDK5GSK3AGSK3BCCNA2CDK2
SCHEMBL1250465 0.80 CDK5 (0.74) CDK5GSK3AGSK3BCCNA2CDK2
SCHEMBL1251123 0.79 MAPT (0.64) CDK5GSK3AGSK3BCCNA2CDK2
SCHEMBL6608787 0.78 CDK5 (0.67) CDK5GSK3AGSK3BCCNA2CDK2
SCHEMBL27591220 0.77 SRD5A2 (0.52) CDK5GSK3AGSK3BCCNA2CDK2
SCHEMBL25609823 0.75 CCNA2 (0.70) CDK5GSK3AGSK3BCDK9CCNA2
SCHEMBL27589430 0.74 CCNA2 (0.51) CDK5GSK3AGSK3BCCNA2CDK2
SCHEMBL4478811 0.73 CCNA2 (0.76) CDK5GSK3AGSK3BCLK2CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1547574-A Novel 2, 4-diaminothiazole derivatives ŵ��Ų�ڿ˹�˾ 2004-11-17 CN disclosed
US-20040210063-A1 Novel 2,4-diaminothiazole derivatives NOVO NORDISK A/S (DK) 2004-10-21 US disclosed
EP-1417188-A1 NOVEL 2,4-DIAMINOTHIAZOLE DERIVATIVES Novo Nordisk A/S (DK) 2004-05-12 EP disclosed
WO-2003011843-A1 NOVEL 2,4-DIAMINOTHIAZOLE DERIVATIVES NOVO NORDISK A/S (DK) 2003-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040210063-A1 Novel 2,4-diaminothiazole derivatives GSK3B, GSK3A, GYS2 CDK5 749/4885GSK3A 2/4885GSK3B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.